Branimir I. Sikic - Publications

Affiliations: 
2002- Medicine/Oncology Stanford University School of Medicine, Palo Alto, CA, United States 

192 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802018. PMID 30811285 DOI: 10.1200/JCO.18.02018  1
2019 Duran GE, Sikic BI. The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance. Plos One. 14: e0210879. PMID 30668583 DOI: 10.1371/journal.pone.0210879  1
2018 Villalobos VM, Wang YC, Sikic BI. Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome Atlas. Jco Clinical Cancer Informatics. 1-16. PMID 30652548 DOI: 10.1200/CCI.17.00096  1
2018 Duran GE, Derdau V, Weitz D, Philippe N, Blankenstein J, Atzrodt J, Sémiond D, Gianolio DA, Macé S, Sikic BI. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein. Cancer Chemotherapy and Pharmacology. PMID 29675746 DOI: 10.1007/s00280-018-3572-1  1
2017 Duran GE, Wang YC, Moisan F, Francisco EB, Sikic BI. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition. British Journal of Cancer. PMID 28399108 DOI: 10.1038/bjc.2017.102  1
2015 Brozovic A, Duran GE, Wang YC, Francisco EB, Sikic BI. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. Molecular Oncology. PMID 26025631 DOI: 10.1016/j.molonc.2015.04.015  1
2015 Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, Brassard D, Vrignaud P, Sikic BI. Mechanisms of resistance to cabazitaxel. Molecular Cancer Therapeutics. 14: 193-201. PMID 25416788 DOI: 10.1158/1535-7163.MCT-14-0155  1
2014 Smith DC, Eisenberg PD, Manikhas G, Chugh R, Gubens MA, Stagg RJ, Kapoun AM, Xu L, Dupont J, Sikic B. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6295-303. PMID 25324140 DOI: 10.1158/1078-0432.CCR-14-1373  1
2014 Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P, Sikic BI. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Molecular Oncology. 8: 1231-9. PMID 24816187 DOI: 10.1016/j.molonc.2014.03.016  1
2014 Sikic BI. Natural and Acquired Resistance to Cancer Therapies The Molecular Basis of Cancer: Fourth Edition. 651-660.e4. DOI: 10.1016/B978-1-4557-4066-6.00047-0  1
2013 Gevaert O, Villalobos V, Sikic BI, Plevritis SK. Identification of ovarian cancer driver genes by using module network integration of multi-omics data. Interface Focus. 3: 20130013. PMID 24511378 DOI: 10.1098/rsfs.2013.0013  1
2012 Lai TL, Lavori PW, Shih MC, Sikic BI. Clinical trial designs for testing biomarker-based personalized therapies. Clinical Trials (London, England). 9: 141-54. PMID 22397801 DOI: 10.1177/1740774512437252  1
2012 Chen KG, Sikic BI. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1863-9. PMID 22344233 DOI: 10.1158/1078-0432.CCR-11-1590  1
2012 Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Investigational New Drugs. 30: 2364-70. PMID 22331549 DOI: 10.1007/s10637-012-9800-3  1
2012 Cabebe EC, Fisher GA, Sikic BI. A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Investigational New Drugs. 30: 1082-7. PMID 21404105 DOI: 10.1007/s10637-011-9656-y  1
2011 Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, Disaia P, Gabra H, Glenn P, Godwin AK, Gross J, Hartmann L, Huang M, Huntsman DG, ... ... Sikic BI, et al. Integrated genomic analyses of ovarian carcinoma Nature. 474: 609-615. PMID 21720365 DOI: 10.1038/nature10166  1
2011 Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, ... ... Sikic BI, et al. NFKBIA deletion in glioblastomas. The New England Journal of Medicine. 364: 627-37. PMID 21175304 DOI: 10.1056/NEJMoa1006312  1
2011 Galatin PS, Advani RH, Fisher GA, Francisco B, Julian T, Losa R, Sierra MI, Sikic BI. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies. Investigational New Drugs. 29: 971-7. PMID 20349264 DOI: 10.1007/s10637-010-9416-4  1
2010 Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI. Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Molecular Cancer Therapeutics. 9: 2970-81. PMID 21062914 DOI: 10.1158/1535-7163.MCT-10-0780  1
2010 O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the children's oncology group Pediatric Blood and Cancer. 54: 694-702. PMID 20209646 DOI: 10.1002/pbc.22366  1
2010 Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 376-81. PMID 19633048 DOI: 10.1093/annonc/mdp292  1
2010 Sikic BI, Tibshirani R, Lacayo NJ. Reply to D.R. Catchpoole et al Journal of Clinical Oncology. 28: e725. DOI: 10.1200/JCO.2010.32.0283  1
2009 Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, et al. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. Jama. 302: 276-89. PMID 19602687 DOI: 10.1001/jama.2009.1022  1
2009 Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, Sikic BI. A network model of a cooperative genetic landscape in brain tumors. Jama. 302: 261-75. PMID 19602686 DOI: 10.1001/jama.2009.997  1
2009 Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leukemia Research. 33: 1055-61. PMID 19108889 DOI: 10.1016/j.leukres.2008.09.015  1
2009 Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leukemia Research. 33: 769-74. PMID 18976810 DOI: 10.1016/j.leukres.2008.09.020  1
2008 Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, Sikic BI. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7074-9. PMID 18981005 DOI: 10.1158/1078-0432.CCR-08-1014  1
2008 Sikic BI, Tibshirani R, Lacayo NJ. Genomics of childhood leukemias: the virtue of complexity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4367-8. PMID 18802145 DOI: 10.1200/JCO.2008.16.4285  1
2007 Juric D, Bredel C, Sikic BI, Bredel M. Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors. Methods in Molecular Biology (Clifton, N.J.). 377: 187-202. PMID 17634618 DOI: 10.1007/978-1-59745-390-5_12  1
2007 Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, Sikic BI. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1341-9. PMID 17312329 DOI: 10.1200/JCO.2006.09.3534  1
2006 Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Investigation. 24: 677-81. PMID 17118777 DOI: 10.1080/07357900600981349  1
2006 Sikic BI. Multidrug resistance and stem cells in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3231-2. PMID 16740740 DOI: 10.1158/1078-0432.CCR-06-0655  1
2006 Cho CD, Fisher GA, Halsey J, Sikic BI. Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Investigational New Drugs. 24: 117-23. PMID 16683204 DOI: 10.1007/s10637-006-2032-7  1
2006 DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 20: 426-32. PMID 16424866 DOI: 10.1038/sj.leu.2404102  1
2006 Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, Chen X, Sikic BI. Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes, Chromosomes & Cancer. 45: 365-74. PMID 16382445 DOI: 10.1002/gcc.20300  1
2006 Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 274-87. PMID 16365179 DOI: 10.1200/JCO.2005.02.9405  1
2006 Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood. 107: 1315-24. PMID 16254147 DOI: 10.1182/blood-2004-08-3218  1
2005 Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI. 893 High-resolution Mapping of Human Glioma Genomes. Neurosurgery. 57: 427-428. PMID 28184830 DOI: 10.1093/neurosurgery/57.2.427b  1
2005 Juric D, Sale S, Hromas RA, Yu R, Wang Y, Duran GE, Tibshirani R, Einhorn LH, Sikic BI. Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proceedings of the National Academy of Sciences of the United States of America. 102: 17763-8. PMID 16306258 DOI: 10.1073/pnas.0509082102  1
2005 Chen KG, Wang YC, Schaner ME, Francisco B, Durán GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, Sikic BI. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Research. 65: 9388-97. PMID 16230402 DOI: 10.1158/0008-5472.CAN-04-4133  1
2005 Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Research. 65: 8679-89. PMID 16204036 DOI: 10.1158/0008-5472.CAN-05-1204  1
2005 Wakelee HA, Sikic BI. Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. Clinical Lung Cancer. 7: S6-12. PMID 16159420  1
2005 Advani R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Investigational New Drugs. 23: 467-77. PMID 16133798 DOI: 10.1007/s10637-005-2906-0  1
2005 Advani R, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, Sikic BI. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 16: 1968-73. PMID 16126736 DOI: 10.1093/annonc/mdi396  1
2005 Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5613-9. PMID 16110021 DOI: 10.1200/JCO.2005.08.359  1
2005 Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, Sikic B, Gelmon KA. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Investigational New Drugs. 23: 311-5. PMID 16012790 DOI: 10.1007/s10637-005-1439-x  1
2005 Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI. High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. Cancer Research. 65: 4088-96. PMID 15899798 DOI: 10.1158/0008-5472.CAN-04-4229  1
2005 Bredel M, Bredel C, Juric D, Kim Y, Vogel H, Harsh GR, Recht LD, Pollack JR, Sikic BI. Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. The Journal of Molecular Diagnostics : Jmd. 7: 171-82. PMID 15858140 DOI: 10.1016/S1525-1578(10)60543-0  1
2004 Dumontet C, Jaffrezou JP, Tsuchiya E, Duran GE, Chen G, Derry WB, Wilson L, Jordan MA, Sikic BI. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bulletin Du Cancer. 91: E81-112. PMID 15568225  1
2004 Tu IP, Schaner M, Diehn M, Sikic BI, Brown PO, Botstein D, Fero MJ. A method for detecting and correcting feature misidentification on expression microarrays. Bmc Genomics. 5: 64. PMID 15357875 DOI: 10.1186/1471-2164-5-64  1
2004 Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, ... Sikic BI, et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood. 104: 2646-54. PMID 15251987 DOI: 10.1182/blood-2003-12-4449  1
2004 Chen GK, Sale S, Tan T, Ermoian RP, Sikic BI. CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Molecular Pharmacology. 65: 906-16. PMID 15044620 DOI: 10.1124/mol.65.4.906  1
2004 Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1078-86. PMID 15020609 DOI: 10.1200/JCO.2004.07.048  1
2004 Bredel M, Bredel C, Sikic BI. Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours? The Lancet. Oncology. 5: 89-100. PMID 14761812 DOI: 10.1016/S1470-2045(04)01382-8  1
2004 Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer. 100: 321-6. PMID 14716767 DOI: 10.1002/cncr.11909  1
2003 Hartman AR, Grekowicz A, Lum BL, Carlson RW, Schurman C, Sikic BI, Shapiro R, Stockdale FE. Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. Breast Cancer Research and Treatment. 82: 61-9. PMID 14672404 DOI: 10.1023/B:BREA.0000003920.27391.ac  1
2003 Lacayo NJ, Duran GE, Sikic BI. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. Journal of Experimental Therapeutics & Oncology. 3: 127-35. PMID 14641819 DOI: 10.1046/j.1359-4117.2003.01088.x  1
2003 Advani R, Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A, Sikic BI. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5187-94. PMID 14613998  1
2003 Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, ... ... Sikic BI, et al. Gene expression patterns in ovarian carcinomas. Molecular Biology of the Cell. 14: 4376-86. PMID 12960427 DOI: 10.1091/mbc.E03-05-0279  1
2002 Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim JH, Fojo T, Oefner PJ, Sikic BI. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Molecular Cancer Therapeutics. 1: 215-25. PMID 12467216  1
2002 Chin DL, Lum BL, Sikic BI. Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 779: 259-69. PMID 12361740 DOI: 10.1016/S1570-0232(02)00395-1  1
2002 Chen GK, Lacayo NJ, Durán GE, Wang Y, Bangs CD, Rea S, Kovacs M, Cherry AM, Brown JM, Sikic BI. Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Genes, Chromosomes & Cancer. 34: 372-83. PMID 12112526 DOI: 10.1002/gcc.10067  1
2002 Sale S, Oefner PJ, Sikic BI. Re: genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. Journal of the National Cancer Institute. 94: 776-7; author reply . PMID 12011233  1
2002 Lacayo NJ, Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN, Bomgaars L, Lauer SJ, Sikic BI, Dahl GV. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia. 16: 920-7. PMID 11986955 DOI: 10.1038/sj.leu.2402455  1
2001 Miller RA, Woodburn KW, Fan Q, Lee I, Miles D, Duran G, Sikic B, Magda D. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 3215-21. PMID 11595717  1
2001 Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 1221-9. PMID 11350887  1
2001 Xu X, Leo C, Jang Y, Chan E, Padilla D, Huang BCB, Lin T, Gururaja T, Hitoshi Y, Lorens JB, Anderson DC, Sikic B, Luo Y, Payan DG, Nolan GP. Dominant effector genetics in mammalian cells Nature Genetics. 27: 23-29. PMID 11137994 DOI: 10.1038/83717  1
2000 Chen GK, Durán GE, Mangili A, Beketic-Oreskovic L, Sikic BI. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. British Journal of Cancer. 83: 892-8. PMID 10970691 DOI: 10.1054/bjoc.2000.1371  1
2000 Cufer T, Pfeifer M, Vrhovec I, Frangez R, Kosec M, Mrhar A, Grabnar I, Golouh R, Vogric S, Sikic BI. Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin. Anti-Cancer Drugs. 11: 303-9. PMID 10898547 DOI: 10.1097/00001813-200004000-00012  1
2000 Yuen AR, Sikic BI. Clinical studies of antisense therapy in cancer. Frontiers in Bioscience : a Journal and Virtual Library. 5: D588-93. PMID 10833467  1
2000 Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, Arceci RJ. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 1867-75. PMID 10784627  1
2000 Lum BL, Kaubisch S, Fisher GA, Brown BW, Sikic BI. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Cancer Chemotherapy and Pharmacology. 45: 305-11. PMID 10755319 DOI: 10.1007/s002800050045  1
2000 Chen GK, Lacayo NJ, Durán GE, Cohen D, Sikic BI. Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335). Molecular Pharmacology. 57: 769-77. PMID 10727524  1
1999 Sikic BI. New approaches in cancer treatment. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 10: 149-53. PMID 10676567  1
1999 Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 3357-63. PMID 10589745  1
1999 Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Covelli A, ... Sikic B, et al. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC) Advances in Experimental Medicine and Biology. 457: 47-56. PMID 10500779  1
1999 Sikic BI. Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology (Williston Park, N.Y.). 13: 183-7. PMID 10370927  1
1999 Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1061-70. PMID 10071301  1
1999 Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. Cancer. 85: 358-67. PMID 10023703 DOI: 10.1002/(SICI)1097-0142(19990115)85:2<358::AID-CNCR13>3.0.CO;2-0  1
1999 Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood. 93: 787-95. PMID 9920827  1
1999 Sikic BI. The First Central European Oncology Congress, Opatija, Croatia, 1998 Annals of Oncology. 10: S1.  1
1998 Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association. 19: 203-9. PMID 9803961  1
1998 Cufer T, Vrhovec I, Pfeifer M, Skrk J, Borstnar S, Sikic BI. Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits. Cancer Chemotherapy and Pharmacology. 41: 517-21. PMID 9554598 DOI: 10.1007/s002800050776  1
1998 Lee CGL, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S, Kim AE, Dintaman JM, Waddell DS, Silverman JA, Duran G, Man M, Sikic B, et al. HIV-1 protease inhibitors and the MDR1 multidrug transporter Journal of Clinical Investigation. 101: 287-288. PMID 9435298  1
1997 Lum BL, Lane KJ, Synold TW, Goram A, Charnick SB, Sikic BI. Validation of a limited sampling model to determine etoposide area under the curve. Pharmacotherapy. 17: 887-90. PMID 9324178  1
1997 Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemotherapy and Pharmacology. 40: S13-9. PMID 9272128  1
1997 Chen G, Durán GE, Steger KA, Lacayo NJ, Jaffrézou JP, Dumontet C, Sikic BI. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. The Journal of Biological Chemistry. 272: 5974-82. PMID 9038218 DOI: 10.1074/jbc.272.9.5974  1
1997 Kühl JS, Krajewski S, Durán GE, Reed JC, Sikic BI. Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia. British Journal of Cancer. 75: 268-74. PMID 9010037  1
1997 Washington CB, Duran GE, Sikic BI, Blaschke TF. Saquinavir is a High affinity substrate for the multidrug transporter, p-glycoprotein Clinical Pharmacology and Therapeutics. 61: 193.  1
1996 Luckie DB, Krouse ME, Law TC, Sikic BI, Wine JJ. Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K+ and Cl- currents in MES-SA cells. The American Journal of Physiology. 270: C1029-36. PMID 8928730  1
1996 Dumontet C, Durán GE, Steger KA, Murphy GL, Sussman HH, Sikic BI. Differential expression of tubulin isotypes during the cell cycle. Cell Motility and the Cytoskeleton. 35: 49-58. PMID 8874965 DOI: 10.1002/(SICI)1097-0169(1996)35:1<49::AID-CM4>3.0.CO;2-D  1
1996 Fisher GA, Lum BL, Hausdorff J, Sikic BI. Pharmacological considerations in the modulation of multidrug resistance. European Journal of Cancer (Oxford, England : 1990). 32: 1082-8. PMID 8763350 DOI: 10.1016/0959-8049(96)00111-6  1
1996 Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Research. 56: 3010-20. PMID 8674056  1
1996 Duran GE, Lau DH, Lewis AD, Kühl JS, Bämmler TK, Sikic BI. Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. Cancer Chemotherapy and Pharmacology. 38: 210-6. PMID 8646794 DOI: 10.1007/s002800050473  1
1996 Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Research. 56: 1091-7. PMID 8640766  1
1996 McCauley DL, Lum BL, Sikic BI. Effect of different mathematical methods on etoposide area under the curve estimations and pharmacodynamic response predictions. Cancer Chemotherapy and Pharmacology. 37: 286-8. PMID 8529291 DOI: 10.1007/BF00688330  1
1995 Jaffrézou JP, Dumontet C, Derry WB, Durán G, Chen G, Tsuchiya E, Wilson L, Jordan MA, Sikic BI. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncology Research. 7: 517-27. PMID 8866664  1
1995 Fisher GA, Lum BL, Sikic BI. The reversal of multidrug resistance. Cancer Treatment and Research. 78: 45-70. PMID 8595147  1
1995 Muller C, Goubin F, Ferrandis E, Cornil-Scharwtz I, Bailly JD, Bordier C, Bénard J, Sikic BI, Laurent G. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells. Molecular Pharmacology. 47: 51-6. PMID 7838133  1
1995 Jaffrézou JP, Chen G, Durán GE, Muller C, Bordier C, Laurent G, Sikic BI, Levade T. Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. Biochimica Et Biophysica Acta. 1266: 1-8. PMID 7718613 DOI: 10.1016/0167-4889(94)00219-5  1
1995 Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematology/Oncology Clinics of North America. 9: 363-82. PMID 7642468  1
1995 Fisher GA, Sikic BI. Drug resistance in clinical oncology and hematology. Introduction. Hematology/Oncology Clinics of North America. 9: xi-xii. PMID 7642462  1
1995 Cufer T, Vrhovec I, Skrk J, Pfeifer M, Pajk B, Zakotnik B, Filipic B, Rode B, Sikic BI. Cyclosporine A increases serum cortisol levels in rabbits. Anti-Cancer Drugs. 6: 615-8. PMID 7579569  1
1995 Marie JP, Simonin G, Legrand O, Delmer A, Faussat AM, Lewis AD, Sikic BI, Zittoun R. Glutathione-S-transferases pi, alpha, mu and mdr1 mRNA expression in normal lymphocytes and chronic lymphocytic leukemia. Leukemia. 9: 1742-7. PMID 7564519  1
1995 Beketic-Oreskovic L, Durán GE, Chen G, Dumontet C, Sikic BI. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. Journal of the National Cancer Institute. 87: 1593-602. PMID 7563202 DOI: 10.1093/jnci/87.21.1593  1
1994 Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 835-42. PMID 8151326  1
1994 Jaffrézou JP, Chen G, Durán GE, Kühl JS, Sikic BI. Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. Journal of the National Cancer Institute. 86: 1152-8. PMID 8028036  1
1994 Lau DH, Duran GE, Lewis AD, Sikic BI. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. British Journal of Cancer. 70: 79-84. PMID 8018545  1
1994 Yuen AR, Sikic BI. Multidrug resistance in lymphomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 2453-9. PMID 7964963  1
1994 Dong Y, Chen G, Durán GE, Kouyama K, Chao AC, Sikic BI, Gollapudi SV, Gupta S, Gardner P. Volume-activated chloride current is not related to P-glycoprotein overexpression. Cancer Research. 54: 5029-32. PMID 7923110  1
1994 Chen G, Jaffrézou JP, Fleming WH, Durán GE, Sikic BI. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Research. 54: 4980-7. PMID 7915196  1
1994 Jaffrézou JP, Sikic BI, Laurent G. Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. Blood. 83: 482-9. PMID 7506953  1
1994 Lau DHM, Duran GE, Sikic BI. Analysis of intracellular retention of morpholinyl anthracyclines in multidrug resistant cancer cells by interactive laser cytometry International Journal of Oncology. 5: 1273-1277.  1
1993 Kühl JS, Durán GE, Chao NJ, Sikic BI. Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. Cancer Chemotherapy and Pharmacology. 33: 10-6. PMID 8269583 DOI: 10.1007/BF00686016  1
1993 Leyland-Jones B, Dalton W, Fisher GA, Sikic BI. Reversal of multidrug resistance to cancer chemotherapy. Cancer. 72: 3484-8. PMID 8242580  1
1993 Lum BL, Gosland MP, Kaubisch S, Sikic BI. Molecular targets in oncology: Implications of the multidrug resistance gene Pharmacotherapy. 13: 88-109. PMID 8097038  1
1993 Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer. 72: 3502-14. PMID 7902206  1
1993 Sikic BI. Multidrug resistance: Clinical relevance in acute leukemia. Commentary II Oncology. 7: 36-38.  1
1992 Lewis AD, Lau DH, Durán GE, Wolf CR, Sikic BI. Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer Research. 52: 4379-84. PMID 1643634  1
1992 Lewis AD, Durán GE, Lau DH, Sikic BI. Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. International Journal of Radiation Oncology, Biology, Physics. 22: 821-4. PMID 1544857 DOI: 10.1016/0360-3016(92)90532-M  1
1992 Sikic BI. Combined chemotherapy and radiotherapy for advanced-stage carcinomas of the cervix Frontiers of Radiation Therapy and Oncology. 26: 153-161. PMID 1511916  1
1992 Kuhl JS, Sikic BI, Blume KG, Chao NJ. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model Experimental Hematology. 20: 1048-1054. PMID 1468539  1
1992 Kühl JS, Sikic BI, Blume KG, Chao NJ. Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model Progress in Clinical and Biological Research. 377: 25-34. PMID 1438422  1
1992 Chao NJ, Aihara M, Kühl JS, Sikic BI, Blume KG. Purging multidrug resistant cells from bone marrow Progress in Clinical and Biological Research. 377: 13-23. PMID 1438409  1
1992 Lau DH, Durán GE, Sikic BI. Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin. Journal of the National Cancer Institute. 84: 1587-92. PMID 1404452  1
1992 Marie JP, Brophy NA, Ehsan MN, Aihara Y, Mohamed NA, Cornbleet J, Chao NJ, Sikic BI. Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells British Journal of Haematology. 81: 145-152. PMID 1353683  1
1991 Sikic BI. Anticancer drug discovery Journal of the National Cancer Institute. 83: 738-740. PMID 2041045  1
1991 Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity Blood. 78: 586-592. PMID 1859877  1
1991 Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN, Sikic BI. The use of probenecid as a chemoprotector against cisplatin nephrotoxicity Cancer. 67: 1518-1524. PMID 1848154  1
1991 Lau DHM, Lewis AD, Ehsan MN, Sikic BI. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin Cancer Research. 51: 5181-5187. PMID 1717140  1
1991 Aihara M, Aihara Y, Schmidt-Wolf G, Schmidt-Wolf I, Sikic BI, Blume KG, Chao NJ. A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy Blood. 77: 2079-2084. PMID 1673356  1
1990 Aihara M, Sikic BI, Blume KG, Chao NJ. Assessment of purging with multidrug resistance (MDR) modulators and VP-16: Results of long-term marrow culture Experimental Hematology. 18: 940-944. PMID 2387345  1
1990 Chao NJ, Aihara M, Blume KG, Sikic BI. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow Experimental Hematology. 18: 1193-1198. PMID 2226679  1
1990 Lau DHM, Ross KL, Sikic BI. Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin Cancer Research. 50: 4056-4060. PMID 2162251  1
1990 Christman JE, Teng NNH, Lebovic GS, Sikic BI. Delivery of a normal infant following cisplatin, vinblastine, and bleomycin (PVB) chemotherapy for malignant teratoma of the ovary during pregnancy Gynecologic Oncology. 37: 292-295. PMID 1693127 DOI: 10.1016/0090-8258(90)90351-K  1
1989 Parce JW, Owicki JC, Kercso KM, Sigal GB, Wada HG, Muir VC, Bousse LJ, Ross KL, Sikic BI, McConnell HM. Detection of cell-affecting agents with a silicon biosensor. Science (New York, N.Y.). 246: 243-7. PMID 2799384  1
1989 Lau DHM, Lewis AD, Sikic BI. Association of DNA cross-linking with potentiation of the morpholino derivative of doxorubicin by human liver microsomes Journal of the National Cancer Institute. 81: 1034-1038. PMID 2733045 DOI: 10.1093/jnci/81.13.1034  1
1989 Gosland MP, Lum BL, Sikic BI. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells Cancer Research. 49: 6901-6905. PMID 2582432  1
1989 Sikic BI. Antitumor antibiotics Current Opinion in Oncology. 1: 198-202. PMID 2489960  1
1988 Schray MF, Martinez A, Howes AE, Podratz KC, Ballon SC, Malkasian GD, Sikic BI. Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 6: 1433-9. PMID 3418375  1
1988 Beckman RA, McFall PJ, Sikic BI, Smith SD. Doxorubicin and the alkylating anthracycline 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin: Comparative in vitro potency against leukemia and bone marrow cells Journal of the National Cancer Institute. 80: 361-365. PMID 3357201  1
1988 Scudder SA, Brown JM, Sikic BI. Dna cross-linking and cytotoxicity of the alkylating cyanomorpholino derivative of doxorubicin in multidrug-resistant cells Journal of the National Cancer Institute. 80: 1294-1298. PMID 3172256 DOI: 10.1093/jnci/80.16.1294  1
1988 Uemura M, Winant RC, Sikic BI, Brandt AE. Characterization and immunoassay of human tumor-associated galactosyltransferase isoenzyme II Cancer Research. 48: 5325-5334. PMID 3136919  1
1988 Coleman CN, Carlson RW, Halsey J, Kohler M, Gribble M, Sikic BI, Jacobs C. Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole Cancer Research. 48: 3528-3532. PMID 2836059  1
1987 Berinstein N, Matthay KK, Papahadjopoulos D, Levy R, Sikic BI. Antibody-directed targeting of liposomes to human cell lines: Role of binding and internalization on growth inhibition Cancer Research. 47: 5954-5959. PMID 3664498  1
1987 Langlotz CP, Fagan LM, Tu SW, Sikic BI, Shortliffe EH. A therapy planning architecture that combines decision theory and artificial intelligence techniques Computers and Biomedical Research. 20: 279-303. PMID 3301187 DOI: 10.1016/0010-4809(87)90059-0  1
1987 Yamauchi T, Raffin TA, Yang P, Sikic BI. Differential protective effects of varying degrees of hypoxia on the cytotoxicities of etoposide and bleomycin. Cancer Chemotherapy and Pharmacology. 19: 282-6. PMID 2439223 DOI: 10.1007/BF00261473  1
1986 Harker WG, Bauer D, Etiz BB, Newman RA, Sikic BI. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: Selectivity for drugs which produce DNA scission Cancer Research. 46: 2369-2373. PMID 3754487  1
1986 Schray MF, Martinez A, Howes AE, Ballon SC, Podratz KC, Sikic BI, Malkasian GD. Advanced epithelial ovarian cancer: toxicity of whole abdominal irradiation after operation, combination chemotherapy, and reoperation. Gynecologic Oncology. 24: 68-80. PMID 3699578 DOI: 10.1016/0090-8258(86)90009-0  1
1986 DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, Sikic BI. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group Cancer Chemotherapy and Pharmacology. 18: 235-238. PMID 3542268 DOI: 10.1007/BF00273393  1
1986 Sikic BI, Scudder SA, Ballon SC, Soriero OM, Christman JE, Suey L, Ehsan MN, Brandt AE, Evans TL. High-dose megestrol acetate therapy of ovarian carcinoma: A phase II study by the Northern California Oncology Group Seminars in Oncology. 13: 26-32. PMID 3099393  1
1986 Chak LY, Zatz LM, Wasserstein P, Cox RS, Kushlan PD, Porzig KJ, Sikic BI. Neurologic dysfunction in patients treated for small cell carcinoma of the lung: A clinical and radiological study International Journal of Radiation Oncology, Biology, Physics. 12: 385-389. PMID 3007408 DOI: 10.1016/0360-3016(86)90355-X  1
1986 Sikic BI. Biochemical and cellular determinants of bleomycin cytotoxicity Cancer Surveys. 5: 81-91. PMID 2439200  1
1986 Zuckerman JE, Raffin TA, Brown JM, Newman RA, Etiz BB, Sikic BI. In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma. Cancer Research. 46: 1748-53. PMID 2418953  1
1985 Turbow MM, Ballon SC, Sikic BI, Koretz MM. Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma Cancer Treatment Reports. 69: 465-467. PMID 4039978  1
1985 Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA Cancer Research. 45: 4091-4096. PMID 4028002  1
1985 Sikic BI, Ehsan MN, Harker WG, Friend NF, Brown BW, Newman RA, Hacker MP, Acton EM. Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog Science. 228: 1544-1546. PMID 4012308 DOI: 10.1126/science.4012308  1
1985 Weber S, Zuckerman JE, Bostwick DG, Bensch KG, Sikic BI, Raffin TA. Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. The Journal of Clinical Investigation. 75: 306-9. PMID 2981251 DOI: 10.1172/JCI111690  1
1985 Picozzi VJ, Sikic BI, Carlson RW, Koretz M, Ballon SC. Bleomycin, mitomycin, and cisplatin therapy for advanced squamous carcinoma of the uterine cervix: A phase II study of the northern California oncology group Cancer Treatment Reports. 69: 903-905. PMID 2410123  1
1985 Levin VA, Byrd D, Sikic BI, Etiz BB, Campbell J, Borcich JK, Davis RL. Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricularly administered bleomycin in beagles Cancer Research. 45: 3810-3815. PMID 2410102  1
1985 Sikic BI, Etiz BB, Harker WG. Mechanisms of multidrug (pleiotropic) resistance in the human sarcoma cell line MES-SA Proceedings of the American Association For Cancer Research. No. 1346.  1
1984 Ballon SC, Portnuff JC, Sikic BI, Turbow MM, Teng NNH, Soriero OM. Second-look laparotomy in epithelial ovarian carcinoma: Precise definition, sensitivity, and specificity of the operative procedure Gynecologic Oncology. 17: 154-160. PMID 6706223 DOI: 10.1016/0090-8258(84)90071-4  1
1983 Harker WG, MacKintosh FR, Sikic BI. Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs Cancer Research. 43: 4943-4950. PMID 6883344  1
1983 Carlson RW, Sikic BI, Turbow MM, Ballon SC. Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary Journal of Clinical Oncology. 1: 645-651. PMID 6199468  1
1983 Muggia FM, Louie AC, Sikic BI. Pulmonary toxicity of antitumor agents Cancer Treatment Reviews. 10: 221-243. PMID 6198083 DOI: 10.1016/0305-7372(83)90012-9  1
1983 Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy Annals of Internal Medicine. 99: 823-833. PMID 6197002  1
1982 Chak LY, Daniels JR, Sikic BI, Torti FM, Lockbaum P, Carter SK. Patterns of failure in small cell carcinoma of the lung Cancer. 50: 1857-1863. PMID 6288227 DOI: 10.1002/1097-0142(19821101)50:9<1857::AID-CNCR2820500933>3.0.CO;2-I  1
1982 Sikic BI, Evans TL, MacKintosh FR, Smith HS. Human tumor clonogenic assays - studies of growth and drug sensitivity Proceedings of the American Association For Cancer Research. No. 732.  1
1981 Sikic BI, Taber RL. Human tumor clonogenic assays - An overview Cancer Chemotherapy and Pharmacology. 6: 201-203. PMID 7318143 DOI: 10.1007/BF00256971  1
1981 MacKintosh FR, Evans TL, Sikic BI. Methodologic problems in clonogenic assays of spontaneous human tumors Cancer Chemotherapy and Pharmacology. 6: 205-210. PMID 7032738 DOI: 10.1007/BF00256972  1
1981 Ahlgren JD, Smith FP, Kerwin DM, Sikic BI, Weiner JH, Schein PS. Pulmonary disease as a complication of chlorozotocin chemotherapy Cancer Treatment Reports. 65: 223-229. PMID 6453644  1
1981 Sikic BI, Evans TL. Bleomycin hydrolase kinetics in the cytosol of malignant and normal tissues Proceedings of the American Association For Cancer Research. 948.  1
1980 Siddik ZH, Drew R, Litterst CL, Mimnaugh EG, Sikic BI, Gram TE. Hepatic cytochrome P-450-dependent metabolism and enzymatic conjugation of foreign compounds in vitamin A-deficient rats Pharmacology. 21: 383-390. PMID 7220590  1
1980 Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF, Woolley PV. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion Cancer Chemotherapy and Pharmacology. 5: 21-26. PMID 6161715 DOI: 10.1007/BF00578558  1
1980 Sikic BI, Siddik ZH, Gram TE. Relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A Cancer Treatment Reports. 64: 659-667. PMID 6159079  1
1979 Drew R, Sikic BI, Mimnaugh EG, Litterst CL, Gram TE. The distribution of 14C-imipramine in mice bearing lewis lung carcinoma Life Sciences. 25: 1813-1820. PMID 529988 DOI: 10.1016/0024-3205(79)90428-4  1
1979 Mimnaugh EG, Siddik ZH, Drew R, Sikic BI, Gram TE. The effects of α-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice Toxicology and Applied Pharmacology. 49: 119-126. PMID 473197 DOI: 10.1016/0041-008X(79)90284-9  1
1979 Siddik ZH, Sikic BI, Drew R, Mimnaugh EG, Litterst CL, Gram TE. Lack of correlation between cortisol-induced precocious maturation of the fetal rabbit lung and drug metabolism Biochemical Pharmacology. 28: 683-685. PMID 444254 DOI: 10.1016/0006-2952(79)90156-4  1
1979 Magin RL, Sikic BI, Cysyk RL. Enhancement of bleomycin activity against Lewis lung tumors in mice by local hyperthermia Cancer Research. 39: 3792-3795. PMID 89905  1
1979 Sikic BI, Siddik ZH, Gram TE. Relative pulmonary toxicity and antitumor effects of two new bleomycin analogues, pepleomycin and tallisomycin A Proceedings of the American Association For Cancer Research. No. 734.  1
1978 Litterst CL, Sikic BI, Mimnaugh EG, Guarino AM, Gram TE. In vitro drug metabolism in male and female athymic, nude mice Life Sciences. 22: 1723-1730. PMID 672423 DOI: 10.1016/0024-3205(78)90624-0  1
1978 Mimnaugh EG, Waring RW, Sikic BI, Magin RL, Drew R, Litterst CL, Gram TE, Guarino AM. Effect of whole-body hyperthermia on the disposition and metabolism of adriamycin in rabbits Cancer Research. 38: 1420-1425. PMID 639069  1
1978 Sikic BI, Collins JM, Mimnaugh EG, Gram TE. Improved therapeutic index of bleomycin when administered by continuous infusion in mice Cancer Treatment Reports. 62: 2011-2017. PMID 87269  1
1978 Sikic BI, Young DM, Mimnaugh EG, Gram TE. Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology Cancer Research. 38: 787-792. PMID 75060  1
1978 Sikic BI, Mimnaugh EG, Gram TE. Effects of schedules of administration of bleomycin on therapy of Lewis lung carcinoma and pulmonary toxicity in mice Proceedings of the American Association For Cancer Research. No. 936.  1
1977 Sikic BI, Mimnaugh EG, Gram TE. Effects of dietary ascorbic acid supplementation on hepatic drug-metabolizing enzymes in the guinea pig Biochemical Pharmacology. 26: 2037-2041. PMID 411495 DOI: 10.1016/0006-2952(77)90013-2  1
1977 Sikic BI, Mimnaugh EG, Litterst CL, Gram TE. The effects of ascorbic acid deficiency and repletion on pulmonary, renal, and hepatic drug metabolism in the guinea pig Archives of Biochemistry and Biophysics. 179: 663-671. PMID 403863 DOI: 10.1016/0003-9861(77)90155-2  1
1977 Gram TE, Litterst CL, Sikic BI, Mimnaugh EG. Comparative aspects of the oxidation and conjugation of foreign chemical compounds by liver and lung Xenobiotica. 7: 106-107.  1
1977 Sikic BI, Mimnaugh EG, Young DM, Gram TE. Dose dependent changes in pulmonary hydroxyproline levels and histopathology during bleomycin treatment in the mouse Pharmacologist. 19: No. 609.  1
1977 Litterst CL, Mimnaugh EG, Sikic BI, Gram TE. In vitro hepatic drug metabolism and enzyme induction in nude athymic mice Federation Proceedings. 36: No.3526.  1
1976 Sikic BI, Baumel IP. The interaction of flurazepam with diphenylhydantoin in the rat Drug Metabolism and Disposition. 4: 584-586. PMID 11981  1
1976 Sikic BI, Mimnaugh EG, Gram TE. Effects of increased levels of dietary ascorbic acid supplementation on hepatic drug metabolism in the guinea pig Pharmacologist. 18: No.227.  1
Show low-probability matches.